Patients characteristics
| N (%) 1012 | |
| Age, (years) | |
| Median | 68.5 |
| Range | 21–91 |
| Elderly (≥70) | 452 (44.7) |
| Sex | |
| Male | 647 (63.9) |
| Female | 365 (36.1) |
| ECOG PS | |
| 0–1 | 870 (86.0) |
| ≥2 | 142 (14.0) |
| Primary tumor | |
| NSCLC | 528 (52.2) |
| Melanoma | 263 (26.0) |
| Renal cell carcinoma | 185 (18.3) |
| Others | 36 (3.6) |
| No of metastatic sites | |
| ≤2 | 522 (51.6) |
| >2 | 490 (48.4) |
| Type of anti-PD-1/PD-L1 agent | |
| Pembrolizumab | 343 (33.9) |
| Nivolumab | 613 (60.6) |
| Atezolizumab | 32 (3.2) |
| Others | 24 (2.3) |
| Treatment line of Immunotherapy | |
| First | 396 (39.1) |
| Non-first | 616 (60.9) |
| BMI (kg/m2) | |
| Median (range) | 25.1 (13.5–50.8) |
| Mean | 25.6 |
| Underweight | 38 (3.8) |
| Normal weight | 460 (45.5) |
| Overweight | 377 (37.3) |
| Obese | 137 (13.5) |
| Baseline steroids | |
| Non-cancer related | 52 (5.1) |
| Cancer related | 211 (20.8) |
| Systemic antibiotics | |
| Prophylaxis | 30 (3.0) |
| Infection | 48 (4.7) |
| Gastric acid suppressant | |
| Prophylaxis | 100 (9.9) |
| Gastritis/GERD | 447 (44.2) |
| Gastric acid suppressant | |
| H2 antagonists | 56 (5.5) |
| Proton pump inhibitors | 491 (48.5) |
| Statins | |
| Yes | 196 (19.4) |
| Other lipid lowerings | |
| Yes | 48 (4.7) |
| Aspirin | |
| Yes | 189 (18.7) |
| Anticoagulants | |
| Yes | 145 (14.3) |
| NSAIDs | |
| Yes | 59 (5.8) |
| ACE inhibitors/ARBs | |
| Yes | 313 (30.9) |
| Calcium antagonist | |
| Yes | 140 (13.8) |
| Beta blockers* | |
| Yes | 114 (12.1) |
| Metformin | |
| Yes | 114 (11.3) |
| Other oral antidiabetics | |
| Yes | 46 (4.5) |
| Opioids† | |
| Yes | 68 (7.4) |
*Available for 943 patients
†Available for 921 patients
ARBs, AngiotensinII receptor blockers; BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group-Performance Status; GERD, gastroesophageal reflux disease; NSCLC, non-small cell lung cancer; PD-1/PD-L1, programmed death-1/programmed death ligand-1.